368
Participants
Start Date
June 26, 2018
Primary Completion Date
August 16, 2019
Study Completion Date
September 5, 2019
BTX 1503
BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
Vehicle
Placebo
St George Dermatology & Skim Cancer Center, Kogarah
Woden Dermatology, Phillip
Sinclair Dermatology, East Melbourne
Varacity Clinical Research, Woolloongabba
The Skin Centre, Benowa
Cmax Clinical Research, Adelaide
North Eastern Health Specialist, Hectorville
Captain Sterline Medical Centre, Nedlands
Burswood Dermatology, Burwood
Fremantle Dermatology, Fremantle
Penn State Hershey Medical, Hershey
Coastal Carolina Research Center, Mt. Pleasant
Greenville Dermatology, LLC, Greenville
Well Phrama Medical Research, Miami
Tory Sullivan, M.D., PA, North Miami Beach
Precision Clinical Research, Sunrise
DS Research - Louisville, Louisville
Aventiv Research, Dublin
Minnesota Clinical Study Center, Fridley
Washington University School of Medicine - Dermatology, St Louis
Medisearch Clinical Trials, Saint Joseph
Delricht Research, New Orleans
Applied Research Center of Arkansas, Little Rock
Suzanne Bruce and Associates, PA, Houston
J&S Studies, Inc., College Station
Avant Research Associates, LLC, Austin
DermReasearch, Austin
JDR Dermatology Research, Las Vegas
Clinical Science Insitute, Santa Monica
Quest Dermatology Research, Northridge
Encino Research Center, Encino
Dermatology Specialist, Inc., Murrieta
Metro Boston Clinical, Brighton
The Acne Treatment and Research Center, Morristown
Clinical Partners, LLC, Johnston
Skin & Canver Foundation Inc., Carlton
Lead Sponsor
Botanix Pharmaceuticals
INDUSTRY